Home›Screener›ITOS›Profile
D
40/100

iTeos Therapeutics

ITOSOncology
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

iTeos Therapeutics (ITOS) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 2[1], 1 Phase 1[2].

No Form 4 insider filings for ITOS were recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR (2026-04-11) ↗
🔬
Clinical Trials
2
NCT05403385Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06547957Advanced Solid Tumors
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Oncology)
NUVBNuvation Bio
B
LBPHLongboard Pharmaceuticals
B
SNDXSyndax Pharmaceuticals
C
KURAKura Oncology, Inc.
C
INCYIncyte Corporation
C
Data Provenance
clinical trial2 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR